Results 171 to 180 of about 2,182,759 (269)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Practical Pointers for Drug Development and Medical Affairs / November 2025

George Klein, Roger Morgan, Melissa Palmer, Freddy Byrth, Michael Fath, Thomas F. Krol, Shabnam Vaezzadeh, Mark Tulchinskiy   +7 more
openalex   +1 more source

DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC ORAL BIOLOGIC DRUG DELIVERY

, 2021
Benjamin P. Wankum
openalex   +1 more source

Machine learning to predict food effects during drug development: a comprehensive review. [PDF]

J Cheminform
Shah A, Bi F, Yang J.
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Development of A Novel NanoBRET High-Throughput Drug Screening Assay for Human GnRH Receptor Using Sulfo-cyanine 5 Fluorophore

Li Shen, Xiaozhe Du, Yakai Yang, Ming Su, Rong Rong, Jia Meng, Lee Wei Lim, David G. Fernig, Zhi-Liang Lu   +8 more
openalex   +1 more source

Add-on combination therapy with monoclonal antibodies: Implications for drug development. [PDF]

J Prev Alzheimers Dis
Cummings J, Burstein AH, Fillit H.
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

275 Flow cytometry and nanoString provide a comprehensive cell- and gene-based tumor profile following checkpoint inhibition in a murine bladder cancer model

Journal for ImmunoTherapy of Cancer, 2021
David Draper, Philip Lapinski, Scott Wise   +2 more
doaj   +1 more source

RP-HPLC-PDA Method Development, Validation and Stability Studies of the Novel Antineoplastic Drug Combination - Decitabine and Cedazuridine

, 2020
B. Mohammed Ishaq, L. Siva Sanker Reddy, S. Venu, M. Sreenivasulu, K. Vanitha Prakash   +4 more
openalex   +2 more sources